P/B
2,5
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
$1.2B
Market Cap • 10/9/2026
2018
(8 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,1
EPS
—
Market Cap
Market Cap
1,2B
EV
661,9M
EV/Revenue
0
EV/EBITDA
-3,3
EV/EBIT
-3,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-17%
Total Yield
-17%
Payout
0%
Retained Earnings
-470,6M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
258,1%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,5
Debt/Equity
0%
Current Ratio
11,6
Quick Ratio
11,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!